CardiovascularInvestigational

Adrenomedullin

Intravenous

Overview

Adrenomedullin is a 52-amino acid peptide hormone produced by vascular endothelial and smooth muscle cells with potent vasodilatory and natriuretic properties. It signals through calcitonin receptor-like receptor complexed with receptor activity-modifying proteins, increasing cyclic AMP to promote vasodilation, angiogenesis, and anti-inflammatory effects.

Mechanism of Action

Adrenomedullin also modulates vascular permeability and exhibits cardioprotective and renoprotective actions..

Research Summary & Key Findings

Plasma adrenomedullin levels correlate with severity and prognosis in heart failure and sepsis, with biomarker studies validating its prognostic utility. Synthetic analogues and stabilized forms are under investigation, though no adrenomedullin-based therapeutic has achieved regulatory approval for cardiovascular indications to date.

Clinical Status

Investigational

Adrenomedullin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Adrenomedullin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Adrenomedullin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.